Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toon Laeremans

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Frontiers in Immunology|June 20, 2022
The Extended N-Terminal Domain Confers Atypical Chemokine Receptor Properties to CXCR3-BGiulia D'Uonnolo, Nathan Reynders, Max Meyrath, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
Structural Basis of μ-Opioid Receptor-Targeting by a Nanobody AntagonistJun Yu, Amit Kumar, Xuefeng Zhang, et al.
Nature Protocols|March 1, 2014
A general protocol for the generation of Nanobodies for structural biologyEls Pardon, Toon Laeremans, Sarah Triest, et al.
Mabs|May 24, 2016
DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loopsBas van der Woning, Gitte De Boeck, Christophe Blanchetot, et al.
Cancer Immunology, Immunotherapy : CII|June 2, 2006
Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR NanobodiesRob C Roovers, Toon Laeremans, Lieven Huang, et al.
Molecular Cancer Therapeutics|August 30, 2008
Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technologyBernard M Tijink, Toon Laeremans, Marianne Budde, et al.
The EMBO Journal|March 21, 2013
Structure of a bacterial type IV secretion core complex at subnanometre resolutionAngel Rivera-Calzada, Rémi Fronzes, Christos G Savva, et al.
Frontiers in Molecular Biosciences|June 9, 2022
Accelerating GPCR Drug Discovery With Conformation-Stabilizing VHHsToon Laeremans, Zara A Sands, Pieter Claes, et al.
Nature Communications|October 9, 2024
Structural basis of μ-opioid receptor targeting by a nanobody antagonistJun Yu, Amit Kumar, Xuefeng Zhang, et al.
Nature Communications|June 16, 2019
Domain-interface dynamics of CFTR revealed by stabilizing nanobodiesMaud Sigoillot, Marie Overtus, Magdalena Grodecka, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Frontiers in Immunology|June 20, 2022
The Extended N-Terminal Domain Confers Atypical Chemokine Receptor Properties to CXCR3-BGiulia D'Uonnolo, Nathan Reynders, Max Meyrath, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
Structural Basis of μ-Opioid Receptor-Targeting by a Nanobody AntagonistJun Yu, Amit Kumar, Xuefeng Zhang, et al.
Nature Protocols|March 1, 2014
A general protocol for the generation of Nanobodies for structural biologyEls Pardon, Toon Laeremans, Sarah Triest, et al.
Mabs|May 24, 2016
DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loopsBas van der Woning, Gitte De Boeck, Christophe Blanchetot, et al.
Cancer Immunology, Immunotherapy : CII|June 2, 2006
Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR NanobodiesRob C Roovers, Toon Laeremans, Lieven Huang, et al.
Molecular Cancer Therapeutics|August 30, 2008
Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technologyBernard M Tijink, Toon Laeremans, Marianne Budde, et al.
The EMBO Journal|March 21, 2013
Structure of a bacterial type IV secretion core complex at subnanometre resolutionAngel Rivera-Calzada, Rémi Fronzes, Christos G Savva, et al.
Frontiers in Molecular Biosciences|June 9, 2022
Accelerating GPCR Drug Discovery With Conformation-Stabilizing VHHsToon Laeremans, Zara A Sands, Pieter Claes, et al.
Nature Communications|October 9, 2024
Structural basis of μ-opioid receptor targeting by a nanobody antagonistJun Yu, Amit Kumar, Xuefeng Zhang, et al.
Nature Communications|June 16, 2019
Domain-interface dynamics of CFTR revealed by stabilizing nanobodiesMaud Sigoillot, Marie Overtus, Magdalena Grodecka, et al.
Pageof 3